peak-20231030

Exhibit 99.1

Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

DENVER, October 30, 2023 - Healthpeak Properties, Inc. (NYSE: PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023.

THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS

–Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0%

–Third quarter new and renewal lease executions totaled 2.3 million square feet:

▪Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 million square foot renewal at Medical City Dallas

▪Lab new and renewal lease executions totaled 211,000 square feet, including leases at three trophy campuses:

•101,000 square feet at 331 Oyster Point in South San Francisco, California

•61,000 square feet at 75 Hayden in Lexington, Massachusetts

▪23,000 square foot development lease at Vantage in South San Francisco, California, bringing the project to 52% pre-leased

–In September 2023, the Cambridge City Council unanimously approved a comprehensive rezoning to allow for greater density and developable heights in the West Cambridge neighborhood of Alewife, where Healthpeak owns a total of 39 acres

–Net debt to Adjusted EBITDAre was 5.2x as of September 30, 2023

–Updated full year 2023 diluted earnings guidance to a range of $0.53 – $0.55 per share; increased the midpoint of 2023 FFO as Adjusted guidance by $0.02 per share and increased Total Portfolio Same-Store Cash (Adjusted) NOI growth guidance by 75 basis points at the midpoint

–On October 29, 2023, Healthpeak's Board of Directors declared a quarterly common stock cash dividend of $0.30 per share to be paid on November 20, 2023, to stockholders of record as of the close of business on November 7, 2023

–Received the GRESB Green Star designation for the twelfth consecutive year and recognized for leading corporate governance and ESG disclosures by Governance Intelligence and IR Magazine

THIRD QUARTER COMPARISON


	Three Months Ended September 30, 2023				Three Months Ended September 30, 2022
(in thousands, except per share amounts)	Amount		Per Share		Amount		Per Share
Net income, diluted	$	64,048	$	0.12	$	355,721	$	0.65
Nareit FFO, diluted	252,566		0.46		227,426		0.42
FFO as Adjusted, diluted	251,647		0.45		235,504		0.43
AFFO, diluted	219,645		0.40		194,963		0.36

Page 1

YEAR TO DATE COMPARISON


	Nine Months Ended September 30, 2023				Nine Months Ended September 30, 2022
(in thousands, except per share amounts)	Amount		Per Share		Amount		Per Share
Net income, diluted	$	233,497	$	0.43	$	496,341	$	0.91
Nareit FFO, diluted	730,764		1.32		711,713		1.30
FFO as Adjusted, diluted	735,067		1.33		711,515		1.30
AFFO, diluted	652,839		1.18		595,883		1.09

Nareit FFO, FFO as Adjusted, AFFO, Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "September 30, 2023 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.

SAME-STORE ("SS") OPERATING SUMMARY

The table below outlines the year-over-year three-month and year-to-date SS Cash (Adjusted) NOI growth.


Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth
	Three Month				Year-To-Date
	SS Growth %		% of SS		SS Growth %		% of SS
Lab	3.3	%	47.6	%	4.3	%	47.3	%
Outpatient Medical	3.4	%	41.1	%	3.2	%	41.5	%
CCRC	32.1	%	11.3	%	20.0	%	11.2	%
Total Portfolio	6.0	%	100.0	%	5.4	%	100.0	%

Page 2

DEVELOPMENT UPDATES

VANTAGE PHASE I

In September 2023, Healthpeak signed an additional 23,000 square foot lease with a global pharmaceutical company at its Vantage Phase I development in South San Francisco, California, bringing the property to 52% pre-leased.

Strategically located on Forbes Boulevard and at the doorstep of Genentech's headquarters, the purpose-built lab campus will feature state-of-the-art design, an amenity center, flexible and efficient floor plates, and building systems accommodating a broad range of lab uses.

WEST CAMBRIDGE

In September 2023, the Cambridge City Council unanimously approved a comprehensive rezoning to allow for greater density and developable heights in the West Cambridge neighborhood of Alewife. Healthpeak’s vision for the neighborhood incorporates Alewife’s historic heritage and its innovative future by creating an active public realm driven by world-class real estate including lab, R&D and multi-family residential. Healthpeak owns a total of 39 acres in Alewife.

GRAPHITE BIO LEASE MODIFICATION

In October 2023, Healthpeak modified an approximately 85,200 square foot lease with Graphite Bio (Nasdaq: GRPH) at the Nexus on Grand campus in South San Francisco, California. Under the terms of the modification, Graphite Bio’s lease expiration date was accelerated to December 31, 2024 in exchange for total consideration of $58 million, consisting of:

i.$37 million cash payment, which is inclusive of the prepayment of Graphite Bio's 2024 contractual rent, including operating expense reimbursements, and termination and related fees; and

ii.$21 million credit for future rent and operating expense reimbursements from the in-place 32,000 square foot subtenant; the subtenant has approximately one year remaining on the sublease, at which point it will become a direct tenant of Healthpeak with a lease term of approximately six years

The $58 million in total consideration is equivalent to approximately 5+ years of Graphite Bio’s original contractual rental payments, including operating expense reimbursements, and provides ample time for Healthpeak to release the remaining 53,000 square feet of fully built-out, Class A space to new tenants. Healthpeak retains the right to immediately release this space with no change in the payments due from Graphite Bio or the subtenant.

ESG

Healthpeak received the GRESB Green Star designation for the twelfth consecutive year. Healthpeak was also named a finalist by Governance Intelligence and IR Magazine for Best Proxy Statement for the fourth consecutive year and Best ESG Reporting for the second consecutive year, and included in Fortune's list of Best Workplaces in Real Estate for the second consecutive year.

To learn more about Healthpeak's commitment to responsible business and view our 2022 ESG Report, please visit www.healthpeak.com/ESG.

DIVIDEND

On October 29, 2023, Healthpeak's Board declared a quarterly common stock cash dividend of $0.30 per share to be paid on November 20, 2023, to stockholders of record as of the close of business on November 7, 2023.

2023 GUIDANCE

We are updating the following guidance ranges for full year 2023:

▪Diluted earnings per common share from $0.49 – $0.53 to $0.53 – $0.55

▪Diluted Nareit FFO per share from $1.72 – $1.76 to $1.76 – $1.78

▪Diluted FFO as Adjusted per share from $1.73 – $1.77 to $1.76 – $1.78

▪Total Portfolio Same-Store Cash (Adjusted) NOI growth from 3.25% – 4.75% to 4.25% – 5.25%

These estimates do not reflect the potential impact from unannounced future transactions. These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2023. For additional details and assumptions underlying this guidance, please see page 38 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com.

UPDATED CONFERENCE CALL INFORMATION

Healthpeak has scheduled a conference call and webcast for Monday, October 30, 2023, at 8:30 a.m. Eastern Time.

The conference call can be accessed in the following ways:

•Healthpeak’s website: https://ir.healthpeak.com/news-events

•Webcast: https://events.q4inc.com/attendee/248022751. Joining via webcast is recommended for those who will not be asking questions.

•Telephone: The participant dial-in number is (888) 330-2513 or (240) 789-2726 (international). The conference ID number is 58822.

An archive of the webcast will be available on Healthpeak's website through October 30, 2024, and a telephonic replay can be accessed through November 6, 2023, by dialing (800) 770-2030 or (647) 362-9199 (international) and entering conference ID number 58822.

ABOUT HEALTHPEAK

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates and develops high-quality real estate for healthcare discovery and delivery.

FORWARD-LOOKING STATEMENTS

Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, capital recycling plans, financing activities, or other transactions discussed in this release; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2023 Guidance." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends, including inflation, interest rates, labor costs, and unemployment; the ability of our existing and future tenants, operators, and borrowers to conduct their respective businesses in a manner that generates sufficient income to make rent and loan payments to us; the financial condition of our tenants, operators, and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement activity risks, including project abandonments, project delays, and lower profits than expected; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our properties operated through RIDEA structures; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions, and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental

compliance costs and liabilities associated with our real estate investments; epidemics, pandemics, or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread; the loss or limited availability of our key personnel; our reliance on information technology systems and the potential impact of system failures, disruptions, or breaches; increased borrowing costs, including due to rising interest rates; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, volatility or uncertainty in the capital markets, and other factors; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; bank failures or other events affecting financial institutions; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a REIT; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

CONTACT

Andrew Johns, CFA

Senior Vice President – Investor Relations

720-428-5400

Healthpeak Properties, Inc.

Consolidated Balance Sheets

In thousands, except share and per share data


	September 30, 2023		December 31, 2022
Assets
Real estate:
Buildings and improvements	$	13,097,282	$	12,784,078
Development costs and construction in progress	863,341		760,355
Land and improvements	2,657,602		2,667,188
Accumulated depreciation and amortization	(3,498,077)		(3,188,138)
Net real estate	13,120,148		13,023,483

Loans receivable, net of reserves of $8,023 and $8,280	225,881		374,832
Investments in and advances to unconsolidated joint ventures	745,381		706,677
Accounts receivable, net of allowance of $2,077 and $2,399	59,085		53,436
Cash and cash equivalents	63,478		72,032
Restricted cash	50,449		54,802
Intangible assets, net	339,191		418,061
Assets held for sale, net	8,277		49,866
Right-of-use asset, net	233,480		237,318
Other assets, net	757,164		780,722
Total assets	$	15,602,534	$	15,771,229

Liabilities and Equity
Bank line of credit and commercial paper	$	424,000	$	995,606
Term loans	496,603		495,957
Senior unsecured notes	5,401,461		4,659,451
Mortgage debt	342,349		346,599
Intangible liabilities, net	133,668		156,193
Liabilities related to assets held for sale, net	39		4,070
Lease liability	204,762		208,515
Accounts payable, accrued liabilities, and other liabilities	687,650		772,485
Deferred revenue	879,174		844,076
Total liabilities	8,569,706		8,482,952

Commitments and contingencies


Redeemable noncontrolling interests	49,016		105,679

Common stock, $1.00 par value: 750,000,000 shares authorized; 547,072,311 and 546,641,973 shares issued and outstanding	547,072		546,642
Additional paid-in capital	10,401,994		10,349,614
Cumulative dividends in excess of earnings	(4,528,508)		(4,269,689)
Accumulated other comprehensive income (loss)	36,747		28,134
Total stockholders’ equity	6,457,305		6,654,701

Joint venture partners	313,402		327,721
Non-managing member unitholders	213,105		200,176
Total noncontrolling interests	526,507		527,897

Total equity	6,983,812		7,182,598

Total liabilities and equity	$	15,602,534	$	15,771,229

Healthpeak Properties, Inc.

Consolidated Statements of Operations

In thousands, except per share data


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Revenues:
Rental and related revenues	$	417,075	$	392,301	$	1,219,473	$	1,149,530
Resident fees and services	133,808		122,142		391,076		369,062
Interest income	5,360		5,963		16,802		16,950
Income from direct financing leases	—		—		—		1,168
Total revenues	556,243		520,406		1,627,351		1,536,710

Costs and expenses:
Interest expense	50,510		44,078		147,547		123,531
Depreciation and amortization	184,559		173,190		561,357		531,412
Operating	232,734		220,208		677,659		642,499
General and administrative	23,093		24,549		73,576		73,161
Transaction costs	36		728		3,098		1,636

Impairments and loan loss reserves (recoveries), net	(550)		3,407		(156)		3,678
Total costs and expenses	490,382		466,160		1,463,081		1,375,917
Other income (expense):
Gain (loss) on sales of real estate, net	—		(4,149)		86,463		10,047

Other income (expense), net	1,481		305,678		4,208		326,855
Total other income (expense), net	1,481		301,529		90,671		336,902

Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	67,342		355,775		254,941		497,695
Income tax benefit (expense)	(787)		3,834		(2,225)		3,775
Equity income (loss) from unconsolidated joint ventures	2,101		(325)		6,646		2,141
Income (loss) from continuing operations	68,656		359,284		259,362		503,611

Income (loss) from discontinued operations	—		(1,298)		—		2,011

Net income (loss)	68,656		357,986		259,362		505,622
Noncontrolling interests’ share in continuing operations	(4,442)		(4,016)		(24,297)		(11,701)

Net income (loss) attributable to Healthpeak Properties, Inc.	64,214		353,970		235,065		493,921

Participating securities’ share in earnings	(166)		(604)		(1,568)		(2,523)
Net income (loss) applicable to common shares	$	64,048	$	353,366	$	233,497	$	491,398

Basic earnings (loss) per common share:
Continuing operations	$	0.12	$	0.66	$	0.43	$	0.91
Discontinued operations	—		0.00		—		0.00
Net income (loss) applicable to common shares	$	0.12	$	0.66	$	0.43	$	0.91

Diluted earnings (loss) per common share:
Continuing operations	$	0.12	$	0.65	$	0.43	$	0.91
Discontinued operations	—		0.00		—		0.00
Net income (loss) applicable to common shares	$	0.12	$	0.65	$	0.43	$	0.91

Weighted average shares outstanding:
Basic	547,062		538,417		546,978		539,105
Diluted	547,331		546,015		547,247		544,852

Healthpeak Properties, Inc.

Funds From Operations

In thousands, except per share data


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Net income (loss) applicable to common shares	$	64,048	$	353,366	$	233,497	$	491,398
Real estate related depreciation and amortization	184,559		173,190		561,357		531,412
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures	6,190		8,704		18,076		19,049
Noncontrolling interests’ share of real estate related depreciation and amortization	(4,571)		(4,464)		(14,042)		(14,487)

Loss (gain) on sales of depreciable real estate, net	—		5,280		(86,463)		(11,408)
Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures	—		239		—		89
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net	—		—		11,546		12
Loss (gain) upon change of control, net(1)	—		(311,438)		(234)		(311,438)
Taxes associated with real estate dispositions	—		197		—		31



Nareit FFO applicable to common shares	250,226		225,074		723,737		704,658
Distributions on dilutive convertible units and other	2,340		2,352		7,027		7,055
Diluted Nareit FFO applicable to common shares	$	252,566	$	227,426	$	730,764	$	711,713
Diluted Nareit FFO per common share	$	0.46	$	0.42	$	1.32	$	1.30
Weighted average shares outstanding - diluted Nareit FFO	554,614		546,015		554,535		546,677
Impact of adjustments to Nareit FFO:
Transaction-related items	$	49	$	681	$	2,993	$	1,573
Other impairments (recoveries) and other losses (gains), net(2)	(602)		2,897		557		(5,874)
Restructuring and severance-related charges	—		—		1,368		—



Casualty-related charges (recoveries), net(3)	(367)		4,514		(610)		4,103



Total adjustments	(920)		8,092		4,308		(198)
FFO as Adjusted applicable to common shares	249,306		233,166		728,045		704,460
Distributions on dilutive convertible units and other	2,341		2,338		7,022		7,055
Diluted FFO as Adjusted applicable to common shares	$	251,647	$	235,504	$	735,067	$	711,515
Diluted FFO as Adjusted per common share	$	0.45	$	0.43	$	1.33	$	1.30
Weighted average shares outstanding - diluted FFO as Adjusted	554,614		546,015		554,535		546,677

_______________________________________

(1)The three and nine months ended September 30, 2022 include a gain upon change of control related to the sale of a 30% interest to a sovereign wealth fund and deconsolidation of seven previously consolidated lab buildings in South San Francisco, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations.

(2)The nine months ended September 30, 2022 includes the following, which are included in other income (expense), net in the Consolidated Statements of Operations: (i) a $23 million gain on sale of a hospital under a direct financing lease and (ii) $14 million of expenses incurred for tenant relocation and other costs associated with the demolition of an outpatient medical building. The three and nine months ended September 30, 2023 and 2022 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.

(3)Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations.

Healthpeak Properties, Inc.

Adjusted Funds From Operations

In thousands


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
FFO as Adjusted applicable to common shares	$	249,306	$	233,166	$	728,045	$	704,460
Stock-based compensation amortization expense	3,434		4,614		10,966		14,635
Amortization of deferred financing costs	3,054		2,691		8,828		8,069
Straight-line rents(1)	(7,279)		(12,965)		(12,710)		(36,837)

AFFO capital expenditures	(24,031)		(24,358)		(66,264)		(75,103)


Deferred income taxes	(430)		(2,814)		(933)		(3,741)
Amortization of above (below) market lease intangibles, net	(5,626)		(5,876)		(20,267)		(17,528)
Other AFFO adjustments	(1,123)		(1,144)		(1,852)		(3,017)
AFFO applicable to common shares	217,305		193,314		645,813		590,938
Distributions on dilutive convertible units and other	2,340		1,649		7,026		4,945
Diluted AFFO applicable to common shares	$	219,645	$	194,963	$	652,839	$	595,883
Diluted AFFO per common share	$	0.40	$	0.36	$	1.18	$	1.09
Weighted average shares outstanding - diluted AFFO	554,614		544,190		554,535		544,852

_______________________________________

(1)The nine months ended September 30, 2023 includes an $8.7 million write-off of straight-line rent receivable associated with Sorrento Therapeutics, Inc., which commenced voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. This write-off is reflected as a reduction of rental and related revenues in the Consolidated Statements of Operations.

Exhibit 99.3

Discussion and

Reconciliation of Non-

GAAP Financial Measures

September 30, 2023

(Unaudited)


Definitions

Adjusted Fixed Charge Coverage Adjusted EBITDAre divided by Fixed Charges. Adjusted Fixed Charge Coverage is a supplemental measure of liquidity and our ability to meet interest payments on our outstanding debt and pay dividends to our preferred stockholders, if applicable. Our various debt agreements contain covenants that require us to maintain ratios similar to Adjusted Fixed Charge Coverage and credit rating agencies utilize similar ratios in evaluating and determining the credit rating on certain of our debt instruments. Adjusted Fixed Charge Coverage is subject to the same limitations and qualifications as Adjusted EBITDAre and Fixed Charges.

Adjusted Funds From Operations (“AFFO”) AFFO is defined as FFO as Adjusted after excluding the impact of the following: (i) stock-based compensation amortization expense, (ii) amortization of deferred financing costs, net, (iii) straight-line rents, (iv) deferred income taxes, (v) amortization of above (below) market lease intangibles, net, and (vi) other AFFO adjustments, which include: (a) non-cash interest related to DFLs and lease incentive amortization (reduction of straight-line rents), (b) actuarial reserves for insurance claims that have been incurred but not reported, and (c) amortization of deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by us and up-front cash payments made by tenants to reduce their contractual rents. Also, AFFO is computed after deducting recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements, and includes adjustments to compute our share of AFFO from our unconsolidated joint ventures. More specifically, recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements (“AFFO capital expenditures”) excludes our share from unconsolidated joint ventures (reported in “other AFFO adjustments”). Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of AFFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our AFFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods (reported in “other AFFO adjustments”). See FFO for further disclosure regarding our use of pro rata share information and its limitations. We believe AFFO is an alternative run-rate earnings measure that improves the understanding of our operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods, and (iii) results among REITs more meaningful. AFFO does not represent cash generated from operating activities determined in accordance with GAAP and is not necessarily indicative of cash available to fund cash needs as it excludes the following items which generally flow through our cash flows from operating activities: (i) adjustments for changes in working capital or the actual timing of the payment of income or expense items that are accrued in the period, (ii) transaction-related costs, (iii) litigation settlement expenses, and (iv) restructuring and severance-related charges. Furthermore, AFFO is adjusted for recurring capital expenditures, which are generally not considered when determining cash flows from operations or liquidity. Other REITs or real estate companies may use different methodologies for calculating AFFO, and accordingly, our AFFO may not be comparable to those reported by other REITs. Management believes AFFO provides a meaningful supplemental measure of our performance and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT, and by presenting AFFO, we are assisting these parties in their evaluation. AFFO is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP and should only be considered together with and as a supplement to our financial information prepared in accordance with GAAP.

Consolidated Debt The carrying amount of bank line of credit, commercial paper, term loans, senior unsecured notes, and mortgage debt, as reported in our consolidated financial statements.

Consolidated Gross Assets The carrying amount of total assets, excluding investments in and advances to our unconsolidated JVs, after adding back accumulated depreciation and amortization, as reported in our consolidated financial statements. Consolidated Gross Assets is a supplemental measure of our financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.

Consolidated Secured Debt Mortgage and other debt secured by real estate, as reported in our consolidated financial statements.

Continuing Care Retirement Community (“CCRC”) A senior housing facility which provides at least three levels of care (i.e., independent living, assisted living and skilled nursing).

Debt Investments Loans secured by a direct interest in real estate and mezzanine loans.

Direct Financing Lease (“DFL”) Lease for which future minimum lease payments are recorded as a receivable and the difference between the future minimum lease payments and the estimated residual values less the cost of the properties is recorded as unearned income. Unearned income is deferred and amortized to income over the lease terms to provide a constant yield.

EBITDAre and Adjusted EBITDAre EBITDAre, or EBITDA for Real Estate, is a supplemental performance measure defined by the National Association of Real Estate Investment Trusts (“Nareit”) and intended for real estate companies. It represents earnings before interest expense, income taxes, depreciation and amortization, gains or losses from sales of depreciable property (including gains or losses on change in control), and impairment charges (recoveries) related to depreciable property. Adjusted EBITDAre is defined as EBITDAre excluding other impairments (recoveries) and other losses (gains), transaction-related items, prepayment costs (benefits) associated with early retirement or payment of debt, restructuring and severance-related charges, litigation costs (recoveries), casualty-related charges (recoveries), stock compensation expense, and foreign currency remeasurement losses (gains), adjusted to reflect the impact of transactions that closed during the period as if the transactions were completed at the beginning of the period. EBITDAre and Adjusted EBITDAre include our pro rata share of our unconsolidated JVs presented on the same basis. We consider EBITDAre and Adjusted EBITDAre important supplemental measures to net income (loss) because they provide an additional manner in which to evaluate our operating performance and serve as additional indicators of our ability to service our debt obligations. Net income (loss) is the most directly comparable U.S. generally accepted accounting principles (“GAAP”) measure to EBITDAre and Adjusted EBITDAre.

Enterprise Debt Consolidated Debt plus our pro rata share of total debt from our unconsolidated JVs. Enterprise Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

Enterprise Gross Assets Consolidated Gross Assets plus our pro rata share of total gross assets from our unconsolidated JVs, after adding back accumulated depreciation and amortization. Enterprise Gross Assets is a supplemental measure of our financial position, which, when used


			2


Definitions

in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.

Enterprise Secured Debt Consolidated Secured Debt plus our pro rata share of mortgage debt from our unconsolidated JVs. Enterprise Secured Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of Enterprise Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

Entrance Fees Certain of our CCRC communities have residency agreements which require the resident to pay an upfront entrance fee prior to taking occupancy at the community. For net income, NOI, Adjusted NOI, Nareit FFO, FFO as Adjusted, and AFFO, the non-refundable portion of the entrance fee is recorded as deferred entrance fee revenue and amortized over the estimated stay of the resident based on an actuarial valuation. The refundable portion of a resident’s entrance fee is generally refundable within a certain number of months or days following contract termination or upon the sale of the unit. All refundable amounts due to residents at any time in the future are classified as liabilities.

Financial Leverage Enterprise Debt divided by Enterprise Gross Assets. Financial Leverage is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share information is calculated by applying our actual ownership percentage for the period and excludes debt funded by us to our JVs. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

Fixed Charges Total interest expense plus capitalized interest plus preferred stock dividends (if applicable). Fixed Charges also includes our pro rata share of the interest expense plus capitalized interest plus preferred stock dividends (if applicable) of our unconsolidated JVs. Fixed Charges is a supplemental measure of our interest payments on outstanding debt and dividends to preferred stockholders for purposes of presenting Fixed Charge Coverage and Adjusted Fixed Charge Coverage. Fixed Charges is subject to limitations and qualifications, as, among other things, it does not include all contractual obligations.

Funds From Operations (“Nareit FFO”) and FFO as Adjusted FFO encompasses Nareit FFO and FFO as Adjusted, each of which is described in detail below. We believe FFO applicable to common shares, diluted FFO applicable to common shares, and diluted FFO per common share are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term FFO was designed by the REIT industry to address this issue.

Nareit FFO. FFO, as defined by the National Association of Real Estate Investment Trusts (“Nareit”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate and other real estate-related depreciation and amortization, and adjustments to compute our share of Nareit FFO and FFO as Adjusted (see below) from joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of Nareit FFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. For consolidated joint ventures in which we do not own 100%, we reflect our share of the equity by adjusting our Nareit FFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. Our pro rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro rata presentations of reconciling items included in Nareit FFO do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.

The presentation of pro rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro rata financial information as a supplement.

Nareit FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute Nareit FFO in accordance with the current Nareit definition; however, other REITs may report Nareit FFO differently or have a different interpretation of the current Nareit definition from ours.

FFO as Adjusted. In addition, we present Nareit FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, transaction-related items, other impairments (recoveries) and other losses (gains), restructuring and severance-related charges, prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), deferred tax asset valuation allowances, and changes in tax legislation (“FFO as Adjusted”). These adjustments are net of tax, when applicable. Transaction-related items include transaction expenses and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Other impairments (recoveries) and other losses (gains) include interest income associated with early and partial repayments of loans receivable and other losses or gains associated with non-depreciable assets including goodwill, DFLs, undeveloped land parcels, and loans receivable. Management believes that FFO as Adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. At the same time


			3


Definitions

that Nareit created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors, and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes certain other adjustments to net income (loss), in addition to adjustments made to arrive at the Nareit defined measure of FFO. FFO as Adjusted is used by management in analyzing our business and the performance of our properties and we believe it is important that stockholders, potential investors, and financial analysts understand this measure used by management. We use FFO as Adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general, and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as Adjusted may not be comparable to those reported by other REITs.

Investment and Portfolio Investment Represents: (i) the carrying amount of real estate assets and intangibles, after adding back accumulated depreciation and amortization and (ii) the carrying amount of DFLs and Debt Investments. Portfolio Investment also includes our pro rata share of the real estate assets and intangibles held in our unconsolidated JVs, presented on the same basis as Investment, and excludes noncontrolling interests' pro rata share of the real estate assets and intangibles held in our consolidated JVs, presented on the same basis. Investment and Portfolio Investment exclude land held for development.

Net Debt Enterprise Debt less the carrying amount of cash and cash equivalents, restricted cash, and expected net proceeds from the future settlement of shares issued through our equity forward contracts, as reported in our consolidated financial statements and our pro rata share of cash and cash equivalents and restricted cash from our unconsolidated JVs. Consolidated Debt is the most directly comparable GAAP measure to Net Debt. Net Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.

Net Debt to Adjusted EBITDAre Net Debt divided by Adjusted EBITDAre is a supplemental measure of our ability to decrease our debt. Because we may not be able to use our cash to reduce our debt on a dollar-for-dollar basis, this measure may have material limitations.

Net Operating Income (“NOI”) and Cash (Adjusted) NOI NOI and Adjusted NOI are non-U.S. generally accepted accounting principles (“GAAP”) supplemental financial measures used to evaluate the operating performance of real estate. NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, income from direct financing leases, and government grant income and exclusive of interest income), less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense. NOI and Adjusted NOI are calculated as NOI and Adjusted NOI from consolidated properties, plus our share of NOI and Adjusted NOI from unconsolidated joint ventures (calculated by applying our actual ownership percentage for the period), less noncontrolling interests’ share of NOI and Adjusted NOI from consolidated joint ventures (calculated by applying our actual ownership percentage for the period). Management utilizes its share of NOI and Adjusted NOI in assessing its performance as we have various joint ventures that contribute to its performance. We do not control our unconsolidated joint ventures, and our share of amounts from unconsolidated joint ventures do not represent our legal claim to such items. Our share of NOI and Adjusted NOI should not be considered a substitute for, and should only be considered together with and as a supplement to, our financial information presented in accordance with GAAP.

Adjusted NOI is oftentimes referred to as “Cash NOI.” Management believes NOI and Adjusted NOI are important supplemental measures because they provide relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and present them on an unlevered basis. We use NOI and Adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our Same-Store (“SS”) performance, as described below. We believe that net income (loss) is the most directly comparable GAAP measure to NOI and Adjusted NOI. NOI and Adjusted NOI should not be viewed as alternative measures of operating performance to net income (loss) as defined by GAAP since they do not reflect various excluded items. Further, our definitions of NOI and Adjusted NOI may not be comparable to the definitions used by other REITs or real estate companies, as they may use different methodologies for calculating NOI and Adjusted NOI.

Operating expenses generally relate to leased outpatient medical and lab buildings, as well as CCRC facilities. We generally recover all or a portion of our leased outpatient medical and lab property expenses through tenant recoveries. We present expenses as operating or general and administrative based on the underlying nature of the expense.

Portfolio Adjusted NOI Portfolio Adjusted NOI is Portfolio Cash Real Estate Revenues less Portfolio Cash Operating Expenses.

Portfolio Operating Expenses and Portfolio Cash Operating Expenses Portfolio Operating Expenses and Portfolio Cash Operating Expenses are non-GAAP supplemental measures. Portfolio Operating Expenses represent property level operating expenses (which exclude transition costs). Portfolio Operating Expenses include consolidated operating expenses plus the Company's pro rata share of operating expenses from its unconsolidated JVs less noncontrolling interests' pro rata share of operating expenses from consolidated JVs. Portfolio Cash Operating Expenses represent Portfolio Operating Expenses after eliminating the effects of straight-line rents, lease termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee expense.

Portfolio Income Cash (Adjusted) NOI plus interest income plus our pro rata share of Cash (Adjusted) NOI from our unconsolidated JVs less noncontrolling interests' pro rata share of Cash (Adjusted) NOI from consolidated JVs. Management believes that Portfolio Income is an important supplemental measure because it provides relevant and useful information regarding our performance; specifically, it is a measure of our property level profitability of the Company inclusive of interest income. Management believes that net income (loss) is the most directly comparable GAAP measure to Portfolio Income. Portfolio Income should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items.

Portfolio Real Estate Revenues and Portfolio Cash Real Estate Revenues Portfolio Real Estate Revenues and Portfolio Cash Real Estate Revenues are non-GAAP supplemental measures. Portfolio Real Estate Revenues include rental related revenues, resident fees and services, income from DFLs, and government grant income which is included in Other income (expense), net in our Consolidated Statement of Operations. Portfolio Real Estate Revenues include the Company's pro rata share from unconsolidated JVs presented on the same basis and exclude


			4


Definitions

noncontrolling interests' pro rata share from consolidated JVs presented on the same basis. Portfolio Cash Real Estate Revenues include Portfolio Real Estate Revenues after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, lease termination fees, and the impact of deferred community fee income.

Projected Stabilized Yield Projected Cash (Adjusted) NOI at Stabilization divided by the expected total development costs. Management considers Projected Stabilized Yield a useful metric for investors as it helps provide context to the expected effects that development projects will have on the Company’s future performance once stabilized.

REVPOR The 3-month average Cash Real Estate Revenues per occupied unit for the most recent period available. REVPOR excludes newly completed assets under lease-up, assets sold, acquired or converted to a new operating structure during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. REVPOR cannot be derived from the information presented for the Other portfolio as units reflect 100% of the unit capacities for unconsolidated JVs and revenue is at the Company's pro rata share. All facility occupancy data was derived solely from information provided by operators without independent verification by us. REVPOR relates to our Other non-reportable segment. REVPOR is a metric used to evaluate the revenue-generating capacity and profit potential of our other assets independent of fluctuating occupancy rates. It is also used in comparison against industry and competitor statistics, if known, to evaluate the quality of our other assets.

REVPOR CCRC The 3-month average Cash Real Estate Revenues per occupied unit excluding Cash NREFs for the most recent period available. REVPOR CCRC excludes newly completed assets under lease-up, assets sold, acquired or converted to a new operating structure during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. REVPOR cannot be derived from the information presented for the CCRC portfolio as units reflect 100% of the unit capacities for unconsolidated JVs and revenue is at the Company's pro rata share. All facility occupancy data was derived solely from information provided by operators without independent verification by us. REVPOR CCRC is a metric used to evaluate the revenue-generating capacity and profit potential of our CCRC assets independent of fluctuating occupancy rates. It is also used in comparison against industry and competitor statistics, if known, to evaluate the quality of our CCRC assets.

RIDEA A structure whereby a taxable REIT subsidiary is permitted to rent a healthcare facility from its parent REIT and hire an independent contractor to operate the facility.

Same-Store (“SS”) Same-Store NOI and Cash (Adjusted) NOI information allows us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties, excluding properties within the other non-reportable segments. We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures in Same-Store NOI and Adjusted NOI (see NOI definition above for further discussion regarding our use of pro-rata share information and its limitations). Same-Store NOI and Adjusted NOI exclude government grant income under the CARES Act. Same-Store Adjusted NOI also excludes amortization of deferred revenue from tenant-funded improvements and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis. Properties are included in Same-Store once they are stabilized for the full period in both comparison periods. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space and rental payments have commenced) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. Properties that experience a change in reporting structure are considered stabilized after 12 months in operations under a consistent reporting structure. A property is removed from Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, a change in reporting structure or operator transition has been agreed to, or a significant tenant relocates from a Same-Store property to a non Same-Store property and that change results in a corresponding increase in revenue. We do not report Same-Store metrics for our other non-reportable segments.

Secured Debt Ratio Enterprise Secured Debt divided by Enterprise Gross Assets. Secured Debt Ratio is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share information is calculated by applying our actual ownership percentage for the period and excludes debt funded by us to our JVs. Our pro rata share of Total Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

Segments The Company’s diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) lab; (ii) outpatient medical; and (iii) continuing care retirement community (“CCRC”).

Share of Consolidated Joint Ventures ("JVs") Noncontrolling interests' pro rata share information is prepared by applying noncontrolling interests' actual ownership percentage for the period and is intended to reflect noncontrolling interests' proportionate economic interest in the financial position and operating results of properties in our portfolio.

Share of Unconsolidated Joint Ventures ("JVs") Our pro rata share information is prepared by applying our actual ownership percentage for the period and is intended to reflect our proportionate economic interest in the financial position and operating results of properties in our portfolio.

Stabilized / Stabilization Newly acquired operating assets are generally considered Stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space and rental payments have commenced) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered Stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. Properties that experience a change in reporting structure are considered Stabilized after 12 months in operations under a consistent reporting structure.


			5


Reconciliations

Funds From Operations

In thousands, except per share data


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Net income (loss) applicable to common shares	$	64,048	$	353,366	$	233,497	$	491,398
Real estate related depreciation and amortization	184,559		173,190		561,357		531,412
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures	6,190		8,704		18,076		19,049
Noncontrolling interests’ share of real estate related depreciation and amortization	(4,571)		(4,464)		(14,042)		(14,487)

Loss (gain) on sales of depreciable real estate, net	—		5,280		(86,463)		(11,408)
Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures	—		239		—		89
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net	—		—		11,546		12
Loss (gain) upon change of control, net(1)	—		(311,438)		(234)		(311,438)
Taxes associated with real estate dispositions	—		197		—		31



Nareit FFO applicable to common shares	250,226		225,074		723,737		704,658
Distributions on dilutive convertible units and other	2,340		2,352		7,027		7,055
Diluted Nareit FFO applicable to common shares	$	252,566	$	227,426	$	730,764	$	711,713

Weighted average shares outstanding - diluted Nareit FFO	554,614		546,015		554,535		546,677

Impact of adjustments to Nareit FFO:
Transaction-related items	$	49	$	681	$	2,993	$	1,573
Other impairments (recoveries) and other losses (gains), net(2)	(602)		2,897		557		(5,874)
Restructuring and severance-related charges	—		—		1,368		—


Casualty-related charges (recoveries), net(3)	(367)		4,514		(610)		4,103



Total adjustments	(920)		8,092		4,308		(198)

FFO as Adjusted applicable to common shares	249,306		233,166		728,045		704,460
Distributions on dilutive convertible units and other	2,341		2,338		7,022		7,055
Diluted FFO as Adjusted applicable to common shares	$	251,647	$	235,504	$	735,067	$	711,515

Weighted average shares outstanding - diluted FFO as Adjusted	554,614		546,015		554,535		546,677

FFO as Adjusted applicable to common shares	$	249,306	$	233,166	$	728,045	$	704,460
Stock-based compensation amortization expense	3,434		4,614		10,966		14,635
Amortization of deferred financing costs	3,054		2,691		8,828		8,069
Straight-line rents(4)	(7,279)		(12,965)		(12,710)		(36,837)
AFFO capital expenditures	(24,031)		(24,358)		(66,264)		(75,103)


Deferred income taxes	(430)		(2,814)		(933)		(3,741)
Amortization of above (below) market lease intangibles, net	(5,626)		(5,876)		(20,267)		(17,528)
Other AFFO adjustments	(1,123)		(1,144)		(1,852)		(3,017)
AFFO applicable to common shares	217,305		193,314		645,813		590,938
Distributions on dilutive convertible units and other	2,340		1,649		7,026		4,945
Diluted AFFO applicable to common shares	$	219,645	$	194,963	$	652,839	$	595,883

Weighted average shares outstanding - diluted AFFO	554,614		544,190		554,535		544,852


			6


Reconciliations

Funds From Operations

In thousands, except per share data


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Diluted earnings per common share	$	0.12	$	0.65	$	0.43	$	0.91
Depreciation and amortization	0.34		0.33		1.03		0.98
Loss (gain) on sales of depreciable real estate, net	—		0.01		(0.14)		(0.02)
Loss (gain) upon change of control, net(1)	—		(0.57)		0.00		(0.57)
Taxes associated with real estate dispositions	—		0.00		—		0.00

Diluted Nareit FFO per common share	$	0.46	$	0.42	$	1.32	$	1.30
Transaction-related items	0.00		0.00		0.01		0.00
Other impairments (recoveries) and other losses (gains), net(2)	(0.01)		0.00		0.00		(0.01)
Restructuring and severance-related charges	—		—		0.00		—


Casualty-related charges (recoveries), net(3)	0.00		0.01		0.00		0.01



Diluted FFO as Adjusted per common share	$	0.45	$	0.43	$	1.33	$	1.30
Stock-based compensation amortization expense	0.01		0.01		0.03		0.03
Amortization of deferred financing costs	0.01		0.00		0.02		0.02
Straight-line rents(4)	(0.01)		(0.02)		(0.02)		(0.07)
AFFO capital expenditures	(0.05)		(0.04)		(0.14)		(0.14)
Deferred income taxes	0.00		(0.01)		0.00		(0.01)
Amortization of above (below) market lease intangibles, net	(0.01)		(0.01)		(0.04)		(0.03)
Other AFFO adjustments	0.00		0.00		0.00		(0.01)
Diluted AFFO per common share	$	0.40	$	0.36	$	1.18	$	1.09

______________________________________

(3)Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations.

(4)The nine months ended September 30, 2023 includes an $8.7 million write-off of straight-line rent receivable associated with Sorrento Therapeutics, Inc., which commenced voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. This write-off is reflected as a reduction of rental and related revenues in the Consolidated Statements of Operations.


			7


Reconciliations

Projected Future Operations(1)

Per share data


	Full Year 2023
	Low		High
Diluted earnings per common share	$	0.53	$	0.55
Real estate related depreciation and amortization	1.36		1.36
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures	0.05		0.05
Noncontrolling interests' share of real estate related depreciation and amortization	(0.04)		(0.04)

Loss (gain) on sales of depreciable real estate, net	(0.16)		(0.16)

Noncontrolling interests' share of gain (loss) on sale of depreciable real estate, net	0.02		0.02

Diluted Nareit FFO per common share	$	1.76	$	1.78

Transaction-related items	0.01		0.01
Other impairments (recoveries) and other losses (gains), net	(0.01)		(0.01)

Diluted FFO as Adjusted per common share	$	1.76	$	1.78

Stock-based compensation amortization expense	$	0.03	$	0.03
Amortization of deferred financing costs	0.02		0.02
Straight-line rents	(0.06)		(0.06)
AFFO capital expenditures	(0.19)		(0.19)
Amortization of above (below) market lease intangibles, net	(0.05)		(0.05)

Other AFFO adjustments	0.01		0.01
Diluted AFFO per common share	$	1.52	$	1.54

______________________________________

(1)The foregoing projections reflect management's view of current and future market conditions as of October 30, 2023 including assumptions with respect to rental rates, occupancy levels, development items, and the earnings impact of the events referenced in our earnings press release that was issued on October 30, 2023. However, these projections do not reflect the impact of unannounced future transactions, except as described herein. Our actual results may differ materially from the projections set forth above. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments.


			8


Reconciliations

Projected NOI(1)

In millions

For the projected year 2023 (low)


	Lab		Outpatient Medical		CCRC		Other		Corporate Adjustments		Total
Net income (loss)	$	403	$	229	$	(31)	$	26	$	(311)	$	318
Other income, costs, and expenses excluded from NOI(2)	245		238		141		(9)		305		916
NOI(3)	$	649	$	466	$	109	$	16	$	(6)	$	1,235
Non-SS NOI	(163)		(40)		1		(16)		6		(212)
SS NOI	$	486	$	426	$	111	$	—	$	—	$	1,022
Non-cash adjustments to SS NOI(4)	(20)		(12)		(1)		—		—		(31)
SS Cash (Adjusted) NOI	$	465	$	415	$	110	$	—	$	—	$	991
Non-SS cash NOI	147		37		(1)		16		(4)		195
Cash (Adjusted) NOI(5)	$	613	$	452	$	109	$	16	$	(4)	$	1,185

For the projected year 2023 (high)


	Lab		Outpatient Medical		CCRC		Other		Corporate Adjustments		Total
Net income (loss)	$	410	$	231	$	(27)	$	36	$	(315)	$	334
Other income, costs, and expenses excluded from NOI(2)	245		238		141		(9)		305		921
NOI(3)	$	655	$	468	$	114	$	27	$	(10)	$	1,255
Non-SS NOI	(165)		(40)		1		(27)		10		(221)
SS NOI	$	490	$	428	$	115	$	—	$	—	$	1,032
Non-cash adjustments to SS NOI(4)	(21)		(12)		(1)		—		—		(32)
SS Cash (Adjusted) NOI	$	470	$	417	$	114	$	—	$	—	$	1,001
Non-SS cash NOI	149		37		(1)		27		(18)		194
Cash (Adjusted) NOI(5)	$	619	$	454	$	113	$	27	$	(18)	$	1,195

______________________________________

(2)Represents interest income, gain (loss) on sales of real estate, net, other income (expense), net, income tax benefit (expense), equity income (loss) from unconsolidated joint ventures (excluding NOI), interest expense, depreciation and amortization, general and administrative, transaction costs, and loss on debt extinguishments.

(3)The midpoint of the low and high projected year 2023 total NOI is $1.245 million.

(4)Represents straight-line rents, amortization of market lease intangibles, net, the deferral of community fees, net of amortization, management contract termination expense, actuarial reserves for insurance claims that have been incurred but not reported, and lease termination fees.

(5)The midpoint of the low and high projected year 2023 total Cash (Adjusted) NOI is $1.190 million.


			9


Reconciliations

NOI(1)

In millions

For the year ended December 31, 2022


	Lab		Outpatient Medical		CCRC		Other		Corporate Adjustments		Total
Net income (loss)	$	627	$	210	$	(37)	$	19	$	(303)	$	516
Other income, costs, and expenses excluded from NOI(2)	(12)		239		140		(3)		303		667
NOI	$	615	$	448	$	103	$	17	$	—	$	1,183
Non-SS NOI	(117)		(33)		(7)		(17)		—		(174)
SS NOI	$	498	$	416	$	96	$	—	$	—	$	1,010
Non-cash adjustments to SS NOI(3)	(47)		(14)		2		—		—		(59)
SS Cash (Adjusted) NOI	$	451	$	402	$	98	$	—	$	—	$	951
Non-SS cash NOI	102		31		7		17		—		157
Cash (Adjusted) NOI	$	553	$	433	$	105	$	17	$	—	$	1,108

______________________________________

(1)May not foot, cross foot, or recalculate due to rounding and adjustments made to SS high and low ranges reported by segments.

(3)Represents straight-line rents, amortization of market lease intangibles, net, the deferral of community fees, net of amortization, management contract termination expense, actuarial reserves for insurance claims that have been incurred but not reported, and lease termination fees.


			10


Reconciliations

Enterprise Gross Assets

In thousands


	September 30, 2023

Consolidated total assets(1)	$	15,602,534
Investments in and advances to unconsolidated joint ventures	(745,381)
Accumulated depreciation and amortization of real estate	3,498,077
Accumulated amortization of real estate intangibles	416,712
Accumulated depreciation and amortization of real estate assets held for sale	5,367
Consolidated Gross Assets	$	18,777,309
Healthpeak's share of unconsolidated joint venture gross assets	973,612
Enterprise Gross Assets	$	19,750,921

______________________________________

(1)Consolidated total assets represents total assets on the Consolidated Balance Sheet as of September 30, 2023 presented on page 7 within the Earnings Release and Supplemental Report for the quarter ended September 30, 2023.


Portfolio Investment

In thousands


	September 30, 2023
	Lab		Outpatient Medical		CCRC		Other		Total
Net real estate	$	7,381,926	$	4,077,941	$	1,660,281	$	—	$	13,120,148
Real estate assets held for sale, net	—		8,080		—		—		8,080
Intangible assets, net	78,309		119,596		141,286		—		339,191
Accumulated depreciation and amortization of real estate	1,410,578		1,750,035		337,464		—		3,498,077

Accumulated amortization of real estate intangibles	77,803		143,517		195,392		—		416,712
Accumulated depreciation and amortization of real estate assets held for sale	—		5,367		—		—		5,367
Healthpeak's share of unconsolidated joint venture gross real estate assets	435,942		21,883		—		470,300		928,125
Fully depreciated and amortization real estate and intangibles assets	502,896		676,410		19,270		—		1,198,576
Leasing commissions and other	91,543		70,848		—		—		162,391
Debt investments	—		—		—		191,689		191,689
Land held for development	(693,558)		(4,676)		—		—		(698,234)
Real estate intangible liabilities, gross	(190,922)		(136,853)		—		—		(327,775)
Noncontrolling interests' share of consolidated joint venture real estate and related intangibles	(5,099)		(382,017)		—		—		(387,116)
Portfolio Investment	$	9,089,418	$	6,350,131	$	2,353,693	$	661,989	$	18,455,231


			11


Reconciliations


Revenues

In thousands


	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Lab	$	207,795	$	207,952	$	205,464	$	223,306	$	226,059
Outpatient Medical	184,506		184,293		186,967		186,661		191,016
CCRC	122,142		125,873		127,084		130,184		133,808
Other	5,963		6,350		6,163		5,279		5,360


Total revenues	$	520,406	$	524,468	$	525,678	$	545,430	$	556,243
Lab	—		—		—		—		—
Outpatient Medical	—		—		—		—		—
CCRC	4		—		137		47		—
Other	—		—		—		—		—


Government grant income	$	4	$	—	$	137	$	47	$	—
Lab	—		—		—		—		—
Outpatient Medical	—		—		—		—		—
CCRC	—		—		—		—		—
Other	(5,963)		(6,350)		(6,163)		(5,279)		(5,360)


Less: Interest income	$	(5,963)	$	(6,350)	$	(6,163)	$	(5,279)	$	(5,360)
Lab	2,938		4,285		2,165		1,928		2,425
Outpatient Medical	756		750		745		754		746
CCRC	—		—		—		—		—
Other	18,656		18,969		20,346		20,261		20,572


Healthpeak's share of unconsolidated joint venture real estate revenues	$	22,350	$	24,004	$	23,256	$	22,943	$	23,743
Lab	—		—		—		—		—
Outpatient Medical	—		—		—		—		—
CCRC	—		47		—		—		—
Other	183		—		228		—		—


Healthpeak's share of unconsolidated joint venture government grant income	$	183	$	47	$	228	$	—	$	—
Lab	(55)		(94)		(143)		(151)		(154)
Outpatient Medical	(8,968)		(8,986)		(8,963)		(8,665)		(8,735)
CCRC	—		—		—		—		—
Other	—		—		—		—		—


Noncontrolling interests' share of consolidated joint venture real estate revenues	$	(9,023)	$	(9,080)	$	(9,106)	$	(8,816)	$	(8,889)







Lab	210,678		212,143		207,486		225,083		228,330
Outpatient Medical	176,294		176,057		178,749		178,749		183,027
CCRC	122,146		125,920		127,221		130,231		133,808
Other	18,839		18,969		20,574		20,261		20,572


Portfolio Real Estate Revenues	$	527,957	$	533,089	$	534,030	$	554,324	$	565,737
Lab	(15,231)		(11,786)		(842)		(14,950)		(9,477)
Outpatient Medical	(4,780)		(5,631)		(4,470)		(4,685)		(4,223)
CCRC	—		—		—		—		—
Other	66		55		(8)		17		(5)


Non-cash adjustments to Portfolio Real Estate Revenues	$	(19,945)	$	(17,362)	$	(5,320)	$	(19,618)	$	(13,705)

Continued


			12


Reconciliations

Revenues

In thousands


	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Lab	195,447		200,357		206,644		210,133		218,854
Outpatient Medical	171,514		170,426		174,279		174,064		178,804
CCRC	122,146		125,920		127,221		130,231		133,808
Other	18,905		19,024		20,566		20,278		20,567


Portfolio Cash Real Estate Revenues	$	508,012	$	515,727	$	528,710	$	534,706	$	552,033
Lab	15,231		11,786		842		14,950		9,477
Outpatient Medical	4,780		5,631		4,470		4,685		4,223
CCRC	—		—		—		—		—
Other	(66)		(55)		8		(17)		5


Non-cash adjustments to Portfolio Real Estate Revenues	$	19,945	$	17,362	$	5,320	$	19,618	$	13,705
Lab	(30,695)		(32,558)		(35,238)		(43,185)		(48,767)
Outpatient Medical	(14,296)		(14,603)		(15,864)		(14,907)		(15,313)
CCRC	(4)		(47)		(137)		(232)		(205)
Other	(18,839)		(18,969)		(20,574)		(20,261)		(20,572)


Non-SS Portfolio Real Estate Revenues	$	(63,834)	$	(66,177)	$	(71,813)	$	(78,585)	$	(84,857)
Lab	179,983		179,585		172,248		181,898		179,564
Outpatient Medical	161,998		161,454		162,885		163,842		167,714
CCRC	122,142		125,873		127,084		129,999		133,603
Other	—		—		—		—		—


Portfolio Real Estate Revenue - SS(1)	$	464,123	$	466,912	$	462,217	$	475,739	$	480,881
Lab	(12,957)		(11,368)		744		(11,930)		(5,234)
Outpatient Medical	(4,437)		(5,263)		(4,196)		(4,285)		(3,888)
CCRC	—		—		—		—		—
Other	—		—		—		—		—


Non-cash adjustment to SS Portfolio Real Estate Revenues	$	(17,394)	$	(16,631)	$	(3,452)	$	(16,215)	$	(9,122)
Lab	167,026		168,217		172,992		169,968		174,330
Outpatient Medical	157,561		156,191		158,689		159,557		163,826
CCRC	122,142		125,873		127,084		129,999		133,603
Other	—		—		—		—		—


Portfolio Cash Real Estate Revenue - SS(1)	$	446,729	$	450,281	$	458,765	$	459,524	$	471,759


			13


Reconciliations


Operating Expenses

In thousands


	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Lab	$	55,162	$	56,346	$	57,566	$	54,832	$	60,268
Outpatient Medical	64,782		64,036		64,398		65,350		67,693
CCRC	100,264		100,110		101,124		101,655		104,773
Other	—		—		—		—		—


Operating expenses	$	220,208	$	220,492	$	223,088	$	221,837	$	232,734
Lab	777		1,140		1,182		848		958
Outpatient Medical	313		265		305		288		301
CCRC	—		—		—		—		—
Other	14,599		14,828		15,006		14,618		15,439


Healthpeak's share of unconsolidated joint venture operating expenses	$	15,689	$	16,233	$	16,493	$	15,754	$	16,698
Lab	(21)		(28)		(40)		(35)		(33)
Outpatient Medical	(2,558)		(2,431)		(2,595)		(2,409)		(2,474)
CCRC	—		—		—		—		—
Other	—		—		—		—		—


Noncontrolling interests' share of consolidated joint venture operating expenses	$	(2,579)	$	(2,459)	$	(2,635)	$	(2,444)	$	(2,507)
Lab	55,918		57,458		58,708		55,645		61,193
Outpatient Medical	62,537		61,870		62,108		63,229		65,520
CCRC	100,264		100,110		101,124		101,655		104,773
Other	14,599		14,828		15,006		14,618		15,439


Portfolio Operating Expenses	$	233,318	$	234,266	$	236,946	$	235,147	$	246,925
Lab	(10)		(8)		(10)		(7)		365
Outpatient Medical	(701)		(692)		(649)		(677)		(676)
CCRC	—		(2,299)		(50)		728		—
Other	(10)		8		13		27		22


Non-cash adjustments to Portfolio Operating Expenses	$	(721)	$	(2,991)	$	(696)	$	71	$	(289)
Lab	55,908		57,450		58,698		55,638		61,558
Outpatient Medical	61,836		61,178		61,459		62,552		64,844
CCRC	100,264		97,811		101,074		102,383		104,773
Other	14,589		14,836		15,019		14,645		15,461


Portfolio Cash Operating Expenses	$	232,597	$	231,275	$	236,250	$	235,218	$	246,636
Lab	10		8		10		7		(365)
Outpatient Medical	701		692		649		677		676
CCRC	—		2,299		50		(728)		—
Other	10		(8)		(13)		(27)		(22)


Non-cash adjustments to Portfolio Operating Expenses	$	721	$	2,991	$	696	$	(71)	$	289
Lab	(8,392)		(9,634)		(9,164)		(8,980)		(10,333)
Outpatient Medical	(7,441)		(7,265)		(6,656)		(6,932)		(7,660)
CCRC	(350)		(341)		(446)		(445)		(537)
Other	(14,599)		(14,828)		(15,006)		(14,618)		(15,439)


Non-SS Portfolio Operating Expenses	$	(30,782)	$	(32,068)	$	(31,272)	$	(30,975)	$	(33,969)

Continued


			14


Reconciliations


Operating Expenses

In thousands


	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Lab	47,526		47,824		49,544		46,665		50,860
Outpatient Medical	55,096		54,605		55,452		56,297		57,860
CCRC	99,914		99,769		100,678		101,210		104,236
Other	—		—		—		—		—


Portfolio Operating Expenses - SS(1)	$	202,536	$	202,198	$	205,674	$	204,172	$	212,956
Lab	(10)		(10)		(8)		(6)		(3)
Outpatient Medical	(665)		(655)		(615)		(645)		(643)
CCRC	—		(2,300)		(50)		728		—
Other	—		—		—		—		—


Non-cash adjustment to SS Portfolio Operating Expenses	$	(675)	$	(2,965)	$	(673)	$	77	$	(646)
Lab	47,516		47,814		49,536		46,659		50,857
Outpatient Medical	54,431		53,950		54,837		55,652		57,217
CCRC	99,914		97,469		100,628		101,938		104,236
Other	—		—		—		—		—


Portfolio Cash Operating Expenses - SS(1)	$	201,861	$	199,233	$	205,001	$	204,249	$	212,310


			15


Reconciliations

Revenue

Operating Expenses

In thousands


Nine Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Lab	$	654,829	Lab	$	172,666
Outpatient Medical	564,644		Outpatient Medical	197,442
CCRC	391,076		CCRC	307,551
Other	16,802		Other	—


Total revenues	$	1,627,351	Operating expenses	$	677,659
Lab	—		Lab	2,987
Outpatient Medical	—		Outpatient Medical	895
CCRC	184		CCRC	—
Other	—		Other	45,062


Government grant income	$	184	Healthpeak's share of unconsolidated joint venture operating expenses	$	48,944
Lab	—		Lab	(108)
Outpatient Medical	—		Outpatient Medical	(7,477)
CCRC	—		CCRC	—
Other	(16,802)		Other	—


Less: Interest income	$	(16,802)	Noncontrolling interests' share of consolidated joint venture operating expenses	$	(7,585)
Lab	6,519		Lab	175,545
Outpatient Medical	2,245		Outpatient Medical	190,860
CCRC	—		CCRC	307,551
Other	61,179		Other	45,062


Healthpeak's share of unconsolidated joint venture real estate revenues	$	69,943	Portfolio Operating Expenses	$	719,018
Lab	—		Lab	350
Outpatient Medical	—		Outpatient Medical	(2,005)
CCRC	—		CCRC	679
Other	229		Other	62


Healthpeak's share of unconsolidated joint venture government grant income	$	229	Non-cash adjustments to Portfolio Operating Expenses	$	(914)
Lab	(449)		Lab	175,895
Outpatient Medical	(26,364)		Outpatient Medical	188,855
CCRC	—		CCRC	308,230
Other	—		Other	45,124


Noncontrolling interests' share of consolidated joint venture real estate revenues	$	(26,813)	Portfolio Cash Operating Expenses	$	718,104
Lab	660,899		Lab	(350)
Outpatient Medical	540,525		Outpatient Medical	2,005
CCRC	391,260		CCRC	(679)
Other	61,408		Other	(62)


Portfolio Real Estate Revenues	$	1,654,092	Non-cash Portfolio Cash Operating Expenses	$	914
Lab	(25,268)		Lab	(33,690)
Outpatient Medical	(13,378)		Outpatient Medical	(25,214)
CCRC	—		CCRC	(1,428)
Other	3		Other	(45,062)


Non-cash adjustments to Portfolio Real Estate Revenues	$	(38,643)	Non-SS Portfolio Operating Expenses	$	(105,394)

Continued


			16


Reconciliations

Revenue

Operating Expenses

In thousands


Nine Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Lab	635,631		Lab	141,855
Outpatient Medical	527,148		Outpatient Medical	165,646
CCRC	391,260		CCRC	306,123
Other	61,411		Other	—


Portfolio Cash Real Estate Revenues	$	1,615,450	Portfolio Operating Expenses - SS(1)	$	613,624
Lab	25,268		Lab	(17)
Outpatient Medical	13,378		Outpatient Medical	(1,878)
CCRC	—		CCRC	678
Other	(3)		Other	—


Non-cash adjustments to Portfolio Real Estate Revenues	$	38,643	Non-cash adjustment to SS Portfolio Operating Expenses	$	(1,217)
Lab	(149,517)		Lab	141,838
Outpatient Medical	(55,323)		Outpatient Medical	163,768
CCRC	(574)		CCRC	306,801
Other	(61,408)		Other	—


Non-SS Portfolio Real Estate Revenue	$	(266,822)	Portfolio Cash Operating Expenses - SS(1)	$	612,407
Lab	511,382
Outpatient Medical	485,203
CCRC	390,686
Other	—


Portfolio Real Estate Revenue - SS(1)	$	1,387,271
Lab	(15,831)
Outpatient Medical	(11,122)
CCRC	—
Other	—


Non-cash adjustment to SS Portfolio Real Estate Revenues	$	(26,953)
Lab	495,551
Outpatient Medical	474,081
CCRC	390,686
Other	—


Portfolio Cash Real Estate Revenue - SS(1)	$	1,360,318

______________________________________

(1)The property count used for Portfolio Real Estate Revenues - SS, Portfolio Cash Real Estate Revenues - SS, Portfolio Operating Expenses - SS, and Portfolio Cash Operating Expenses - SS differed for the three and nine months ended September 30, 2023.


			17


Reconciliations


Net Income to Adjusted EBITDAre

In thousands


	Three Months Ended September 30, 2023
Net income (loss)	$	68,656
Interest expense	50,510
Income tax expense (benefit)	787
Depreciation and amortization	184,559
Other depreciation and amortization	2,119



Share of unconsolidated JV:
Interest expense	463
Income tax expense (benefit)	50
Depreciation and amortization	6,190


EBITDAre	$	313,334
Transaction-related items(1)	36
Other impairments (recoveries) and losses (gains)(1)	(550)



Casualty-related charges (recoveries)(1)	(493)
Stock-based compensation amortization expense	3,434

Adjusted EBITDAre	$	315,761


Adjusted Fixed Charge Coverage

In thousands


	Three Months Ended September 30, 2023
Interest expense, including unconsolidated JV interest expense at share	50,973
Capitalized interest, including unconsolidated JV capitalized interest at share	15,151
Fixed Charges	$	66,124

Adjusted Fixed Charge Coverage	4.8x

______________________________________

(1)This amount includes the corresponding line on the Funds From Operations reconciliation on page 6 of this document excluding the related tax impact included in the adjustment for income tax expense (benefit) above.


			18


Reconciliations


Enterprise Debt and Net Debt

In thousands


	September 30, 2023
Bank line of credit and commercial paper	$	424,000
Term loans	496,603
Senior unsecured notes	5,401,461
Mortgage debt	342,349
Consolidated Debt	$	6,664,413
Share of unconsolidated JV mortgage debt	39,976
Enterprise Debt	$	6,704,389
Cash and cash equivalents	(63,478)
Share of unconsolidated JV cash and cash equivalents	(29,947)
Restricted cash	(50,449)
Share of unconsolidated JV restricted cash	(3,126)

Net Debt	$	6,557,389


Financial Leverage

In thousands


	September 30, 2023
Enterprise Debt	$	6,704,389
Enterprise Gross Assets	19,750,921
Financial Leverage	33.9%


Secured Debt Ratio

In thousands


	September 30, 2023
Mortgage debt	$	342,349
Share of unconsolidated JV mortgage debt	39,976
Enterprise Secured Debt	$	382,325
Enterprise Gross Assets	19,750,921
Secured Debt Ratio	1.9%


Net Debt to Adjusted EBITDAre

In thousands

Three Months Ended
September 30, 2023

Net Debt

6,557,389

Annualized Adjusted EBITDAre(1)

1,263,044

Net Debt to Adjusted EBITDAre

5.2x

______________________________________

(1)Represents the current quarter Adjusted EBITDAre multiplied by a factor of four.


			19


Reconciliations


Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS

In thousands


Total Portfolio	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Net income (loss)	$	357,986	$	10,802	$	134,507	$	56,199	$	68,656
Loss (income) from discontinued operations	1,298		(873)		—		—		—
Income (loss) from continuing operations	$	359,284	$	9,929	$	134,507	$	56,199	$	68,656
Interest income	(5,963)		(6,350)		(6,163)		(5,279)		(5,360)
Interest expense	44,078		49,413		47,963		49,074		50,510
Depreciation and amortization	173,190		179,157		179,225		197,573		184,559
General and administrative	24,549		57,872		24,547		25,936		23,093
Transaction costs	728		3,217		2,425		637		36
Impairments and loan loss reserves (recoveries), net	3,407		3,326		(2,213)		2,607		(550)
Loss (gain) on sales of real estate, net	4,149		969		(81,578)		(4,885)		—
Other expense (income), net	(305,678)		587		(772)		(1,955)		(1,481)
Government grant income	4		—		137		47		—

Income tax expense (benefit)	(3,834)		(650)		302		1,136		787
Equity loss (income) from unconsolidated joint ventures	325		156		(1,816)		(2,729)		(2,101)
Healthpeak's share of unconsolidated joint venture NOI	6,844		7,818		6,991		7,189		7,045
Noncontrolling interests' share of consolidated joint venture NOI	(6,444)		(6,621)		(6,471)		(6,372)		(6,382)
Portfolio NOI	$	294,639	$	298,823	$	297,084	$	319,178	$	318,812
Adjustment to Portfolio NOI	(19,224)		(14,371)		(4,624)		(19,688)		(13,416)
Portfolio Cash (Adjusted) NOI	$	275,415	$	284,452	$	292,460	$	299,490	$	305,396
Interest income	5,963		6,350		6,163		5,279		5,360

Portfolio Income	$	281,378	$	290,802	$	298,623	$	304,769	$	310,756
Interest income	(5,963)		(6,350)		(6,163)		(5,279)		(5,360)

Adjustment to Portfolio NOI	19,224		14,371		4,624		19,688		13,416
Non-SS Portfolio NOI	(33,052)		(34,109)		(40,541)		(47,611)		(50,887)
SS Portfolio NOI	$	261,587	$	264,714	$	256,543	$	271,567	$	267,925
Non-cash adjustment to SS Portfolio NOI	(16,719)		(13,666)		(2,779)		(16,292)		(8,475)
SS Portfolio Cash (Adjusted) NOI	$	244,868	$	251,048	$	253,764	$	255,275	$	259,450

Continued


			20


Reconciliations


Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS

In thousands


Lab	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Net income (loss)	$	393,487	$	75,575	$	133,258	$	76,551	$	88,337
Loss (income) from discontinued operations	—		—		—		—		—
Income (loss) from continuing operations	$	393,487	$	75,575	$	133,258	$	76,551	$	88,337


Depreciation and amortization	70,141		74,697		75,582		93,235		78,646

Transaction costs	40		20		158		—		51

Loss (gain) on sales of real estate, net	—		112		(60,498)		—		—
Other expense (income), net	(311,912)		(7)		(4)		2		1


Equity loss (income) from unconsolidated joint ventures	877		1,209		(598)		(1,314)		(1,244)
Healthpeak's share of unconsolidated joint venture NOI	2,161		3,145		983		1,080		1,467
Noncontrolling interests' share of consolidated joint venture NOI	(34)		(66)		(103)		(116)		(121)
Portfolio NOI	$	154,760	$	154,685	$	148,778	$	169,438	$	167,137
Adjustment to Portfolio NOI	(15,221)		(11,778)		(832)		(14,943)		(9,842)
Portfolio Cash (Adjusted) NOI(1)	$	139,539	$	142,907	$	147,946	$	154,495	$	157,295





Adjustment to Portfolio NOI	15,221		11,778		832		14,943		9,842
Non-SS Portfolio NOI	(22,303)		(22,924)		(26,074)		(34,205)		(38,433)
SS Portfolio NOI	$	132,457	$	131,761	$	122,704	$	135,233	$	128,704
Non-cash adjustment to SS Portfolio NOI	(12,947)		(11,358)		752		(11,924)		(5,231)
SS Portfolio Cash (Adjusted) NOI	$	119,510	$	120,403	$	123,456	$	123,309	$	123,473


Outpatient Medical	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Net income (loss)	$	47,663	$	45,571	$	71,064	$	48,068	$	48,906
Loss (income) from discontinued operations	—		—		—		—		—
Income (loss) from continuing operations	$	47,663	$	45,571	$	71,064	$	48,068	$	48,906

Interest expense	1,964		1,970		1,920		1,924		1,947
Depreciation and amortization	70,917		71,983		71,158		71,722		72,736

Transaction costs	94		1,087		132		16		23

Loss (gain) on sales of real estate, net	(554)		235		(21,312)		—		—
Other expense (income), net	(154)		(354)		(204)		(235)		(78)


Equity loss (income) from unconsolidated joint ventures	(206)		(235)		(189)		(184)		(211)
Healthpeak's share of unconsolidated joint venture NOI	443		485		440		466		445
Noncontrolling interests' share of consolidated joint venture NOI	(6,410)		(6,555)		(6,368)		(6,256)		(6,261)
Portfolio NOI	$	113,757	$	114,187	$	116,641	$	115,521	$	117,507
Adjustment to Portfolio NOI	(4,079)		(4,939)		(3,821)		(4,008)		(3,547)
Portfolio Cash (Adjusted) NOI(1)	$	109,678	$	109,248	$	112,820	$	111,513	$	113,960





Adjustment to Portfolio NOI	4,079		4,939		3,821		4,008		3,547
Non-SS Portfolio NOI	(6,855)		(7,338)		(9,208)		(7,976)		(7,653)
SS Portfolio NOI	$	106,902	$	106,849	$	107,433	$	107,545	$	109,854
Non-cash adjustment to SS Portfolio NOI	(3,772)		(4,608)		(3,581)		(3,640)		(3,244)
SS Portfolio Cash (Adjusted) NOI	$	103,130	$	102,241	$	103,852	$	103,905	$	106,610

Continued


			21


Reconciliations


Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS

In thousands


CCRC	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Net income (loss)	$	(19,821)	$	(10,097)	$	(9,227)	$	(5,514)	$	(5,633)
Loss (income) from discontinued operations	—		—		—		—		—
Income (loss) from continuing operations	$	(19,821)	$	(10,097)	$	(9,227)	$	(5,514)	$	(5,633)

Interest expense	1,887		1,881		1,816		1,823		1,830
Depreciation and amortization	32,132		32,477		32,485		32,616		33,177

Transaction costs	594		67		219		278		(85)

Other expense (income), net	7,086		1,435		667		(674)		(254)

Government grant income	4		—		137		47		—

Healthpeak's share of unconsolidated joint venture NOI	—		47		—		—		—

Portfolio NOI	$	21,882	$	25,810	$	26,097	$	28,576	$	29,035
Adjustment to Portfolio NOI	—		2,299		50		(728)		—
Portfolio Cash (Adjusted) NOI(1)	$	21,882	$	28,109	$	26,147	$	27,848	$	29,035





Adjustment to Portfolio NOI	—		(2,299)		(50)		728		—
Non-SS Portfolio NOI	346		294		309		213		332
SS Portfolio NOI	$	22,228	$	26,104	$	26,406	$	28,789	$	29,367
Non-cash adjustment to SS Portfolio NOI	—		2,300		50		(728)		—
SS Portfolio Cash (Adjusted) NOI	$	22,228	$	28,404	$	26,456	$	28,061	$	29,367


Other	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Net income (loss)	$	(1,801)	$	3,221	$	9,173	$	8,769	$	6,503
Loss (income) from discontinued operations	—		—		—		—		—
Income (loss) from continuing operations	$	(1,801)	$	3,221	$	9,173	$	8,769	$	6,503
Interest income	(5,963)		(6,350)		(6,163)		(5,279)		(5,360)




Impairments and loan loss (reserves) recoveries, net	3,407		3,326		(2,213)		2,607		(550)
Loss (gain) on sales of real estate, net	4,703		622		232		(4,885)		—
Other expense (income), net	—		(1)		—		19		53


Equity loss (income) from unconsolidated joint ventures	(346)		(818)		(1,029)		(1,231)		(646)
Healthpeak's share of unconsolidated joint venture NOI	4,240		4,141		5,568		5,643		5,133

Portfolio NOI	$	4,240	$	4,141	$	5,568	$	5,643	$	5,133
Adjustment to Portfolio NOI	76		47		(21)		(9)		(27)
Portfolio Cash (Adjusted) NOI	$	4,316	$	4,188	$	5,547	$	5,634	$	5,106
Interest income	5,963		6,350		6,163		5,279		5,360

Portfolio Income	$	10,279	$	10,538	$	11,710	$	10,913	$	10,466
Interest income	(5,963)		(6,350)		(6,163)		(5,279)		(5,360)

Adjustment to Portfolio NOI	(76)		(47)		21		9		27
Non-SS Portfolio NOI	(4,240)		(4,141)		(5,568)		(5,643)		(5,133)
SS Portfolio NOI	$	—	$	—	$	—	$	—	$	—

SS Portfolio Cash (Adjusted) NOI	$	—	$	—	$	—	$	—	$	—

Continued


			22


Reconciliations


Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS

In thousands


Corporate Non-Segment	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Net income (loss)	$	(61,542)	$	(103,468)	$	(69,761)	$	(71,675)	$	(69,457)
Loss (income) from discontinued operations	1,298		(873)		—		—		—
Income (loss) from continuing operations	$	(60,244)	$	(104,341)	$	(69,761)	$	(71,675)	$	(69,457)
Interest expense	40,227		45,562		44,227		45,327		46,733
General and administrative	24,549		57,872		24,547		25,936		23,093
Transaction costs	—		2,043		1,916		343		47

Other expense (income), net	(698)		(486)		(1,231)		(1,067)		(1,203)
Income tax expense (benefit)	(3,834)		(650)		302		1,136		787
Portfolio NOI	$	—	$	—	$	—	$	—	$	—

______________________________________

(1)Portfolio Income and Portfolio Cash (Adjusted) NOI are the same for Lab, Outpatient Medical, and CCRC for all periods presented as there is no interest income related to such segments.


			23


Reconciliations


Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS

In thousands

For the nine months ended September 30, 2023


	Lab		Outpatient Medical		CCRC		Other Non-reportable		Corporate Non-segment		Total
Net income (loss)	$	298,145	$	168,037	$	(20,374)	$	24,445	$	(210,891)	$	259,362
Loss (income) from discontinued operations	—		—		—		—		—		—
Income (loss) from continuing operations	$	298,145	$	168,037	$	(20,374)	$	24,445	$	(210,891)	$	259,362
Interest income	—		—		—		(16,802)		—		(16,802)
Interest expense	—		5,791		5,470		—		136,286		147,547
Depreciation and amortization	247,463		215,617		98,277		—		—		561,357
General and administrative	—		—		—		—		73,576		73,576
Transaction costs	209		171		412		—		2,306		3,098
Impairments and loan loss (reserves) recoveries, net	—		—		—		(156)		—		(156)
Loss (gain) on sales of real estate, net	(60,498)		(21,312)		—		(4,653)		—		(86,463)

Other expense (income), net	(1)		(517)		(260)		72		(3,502)		(4,208)
Government grant income	—		—		184		—		—		184
Income tax expense (benefit)	—		—		—		—		2,225		2,225
Equity loss (income) from unconsolidated joint ventures	(3,155)		(585)		—		(2,906)		—		(6,646)
Healthpeak's share of unconsolidated joint venture NOI	3,532		1,350		—		16,346		—		21,228
Noncontrolling interests' share of consolidated joint venture NOI	(341)		(18,887)		—		—		—		(19,228)
Portfolio NOI	$	485,354	$	349,665	$	83,709	$	16,346	$	—	$	935,074
Adjustment to NOI	(25,618)		(11,373)		(679)		(59)		—		(37,729)
Portfolio Cash (Adjusted) NOI	$	459,736	$	338,292	$	83,030	$	16,287	$	—	$	897,345
Interest Income	—		—		—		16,802		—		16,802

Portfolio Income	$	459,736	$	338,292	$	83,030	$	33,089	$	—	$	914,147
Interest income	—		—		—		(16,802)		—		(16,802)

Adjustment to NOI	25,618		11,373		679		59		—		37,729
Non-SS Portfolio NOI	(115,827)		(30,108)		854		(16,346)		—		(161,427)
SS Portfolio NOI(1)	$	369,527	$	319,557	$	84,563	$	—	$	—	$	773,647
Non-cash adjustment to SS Portfolio NOI	(15,813)		(9,244)		(678)		—		—		(25,735)
SS Portfolio Cash (Adjusted) NOI(1)	$	353,714	$	310,313	$	83,885	$	—	$	—	$	747,912

______________________________________

(1)The property count used for SS Portfolio NOI and SS Portfolio Cash (Adjusted) NOI differed for the three and nine months ended September 30, 2023 and 2022.


			24


Reconciliations


Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS

In thousands

For the nine months ended September 30, 2022


	Lab		Outpatient Medical		CCRC		Other Non-reportable		Corporate Non-segment		Total
Net income (loss)	$	544,530	$	163,007	$	(32,957)	$	9,304	$	(178,262)	$	505,622
Loss (income) from discontinued operations	—		—		—		—		(2,011)		(2,011)
Income (loss) from continuing operations	$	544,530	$	163,007	$	(32,957)	$	9,304	$	(180,273)	$	503,611
Interest income	—		—		—		(16,950)		—		(16,950)
Interest expense	—		4,931		5,629		—		112,971		123,531
Depreciation and amortization	227,952		207,563		95,897		—		—		531,412
General and administrative	—		—		—		—		73,161		73,161
Transaction costs	367		168		658		—		443		1,636
Impairments and loan loss (reserves) recoveries, net	—		—		—		3,678		—		3,678
Loss (gain) on sales of real estate, net	(3,856)		(10,894)		—		4,703		—		(10,047)

Other expense (income), net	(311,932)		(12,354)		(55)		13		(2,527)		(326,855)
Government grant income	—		—		6,765		—		—		6,765
Income tax expense (benefit)	—		—		—		—		(3,775)		(3,775)
Equity loss (income) from unconsolidated joint ventures	(237)		(617)		(539)		(748)		—		(2,141)
Healthpeak's share of unconsolidated joint venture NOI	3,893		1,337		334		12,611		—		18,175
Noncontrolling interests' share of consolidated joint venture NOI	(115)		(18,846)		—		—		—		(18,961)
Portfolio NOI	$	460,602	$	334,295	$	75,732	$	12,611	$	—	$	883,240
Adjustment to NOI	(50,977)		(10,574)		—		120		—		(61,431)
Portfolio Cash (Adjusted) NOI	$	409,625	$	323,721	$	75,732	$	12,731	$	—	$	821,809
Interest Income	—		—		—		16,950		—		16,950
Portfolio Income	$	409,625	$	323,721	$	75,732	$	29,681	$	—	$	838,759
Interest income	—		—		—		(16,950)		—		(16,950)
Adjustment to NOI	50,977		10,574		—		(120)		—		61,431
Non-SS Portfolio NOI	(84,954)		(23,883)		(5,816)		(12,611)		—		(127,264)
SS Portfolio NOI(1)	$	375,648	$	310,412	$	69,916	$	—	$	—	$	755,976
Non-cash adjustment to SS Portfolio NOI	(36,641)		(9,678)		—		—		—		(46,319)
SS Portfolio Cash (Adjusted) NOI(1)	$	339,007	$	300,734	$	69,916	$	—	$	—	$	709,657

______________________________________

(1)The property count used for SS Portfolio NOI and SS Portfolio Cash (Adjusted) NOI differed for the three and nine months ended September 30, 2023 and 2022.


			25


Reconciliations


Healthpeak's Share of Unconsolidated Joint Venture NOI

In thousands


Total Portfolio	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Equity income (loss) from unconsolidated joint ventures	$	(325)	$	(156)	$	1,816	$	2,729	$	2,101
Depreciation and amortization	8,704		8,642		5,993		5,893		6,190
General and administrative	177		167		444		249		267
Loss (gain) on sales of real estate, net	239		45		—		—		—
Other expense (income), net	(2,069)		(861)		(1,478)		(1,917)		(1,558)
Income tax expense (benefit)	118		(19)		216		235		45

Healthpeak's share of unconsolidated joint venture NOI	$	6,844	$	7,818	$	6,991	$	7,189	$	7,045


Lab	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Equity income (loss) from unconsolidated joint ventures	$	(877)	$	(1,209)	$	598	$	1,314	$	1,244
Depreciation and amortization	3,709		5,037		1,521		1,415		1,568
General and administrative	123		160		345		209		220
Other expense (income), net	(794)		(843)		(1,481)		(1,858)		(1,565)




Healthpeak's share of unconsolidated joint venture NOI	$	2,161	$	3,145	$	983	$	1,080	$	1,467


Outpatient Medical	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Equity income (loss) from unconsolidated joint ventures	$	206	$	235	$	189	$	184	$	211
Depreciation and amortization	225		240		238		256		218
General and administrative	5		3		7		21		15


Income tax expense (benefit)	7		7		6		5		1

Healthpeak's share of unconsolidated joint venture NOI	$	443	$	485	$	440	$	466	$	445


CCRC	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Equity income (loss) from unconsolidated joint ventures	$	—	$	—	$	—	$	—	$	—


Loss (gain) on sales of real estate, net	—		45		—		—		—
Other expense (income), net	—		2		—		—		—


Healthpeak's share of unconsolidated joint venture NOI	$	—	$	47	$	—	$	—	$	—


Other	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Equity income (loss) from unconsolidated joint ventures	$	346	$	818	$	1,029	$	1,231	$	646
Depreciation and amortization	4,770		3,365		4,234		4,222		4,404
General and administrative	49		4		92		19		32

Other expense (income), net	(1,036)		(20)		3		(59)		7
Income tax expense (benefit)	111		(26)		210		230		44

Healthpeak's share of unconsolidated joint venture NOI	$	4,240	$	4,141	$	5,568	$	5,643	$	5,133


			26


Reconciliations


Healthpeak's Share of Unconsolidated Joint Venture NOI

In thousands

For the nine months ended September 30, 2023


	Lab		Outpatient Medical		CCRC		Other		Total
Equity income (loss) from unconsolidated joint ventures	$	3,155	$	585	$	—	$	2,906	$	6,646
Depreciation and amortization	4,504		712		—		12,860		18,076
General and administrative	774		41		—		143		958

Other expense (income), net	(4,901)		—		—		(47)		(4,948)
Income tax expense (benefit)	—		12		—		484		496

Healthpeak's share of unconsolidated joint venture NOI	$	3,532	$	1,350	$	—	$	16,346	$	21,228

For the nine months ended September 30, 2022


	Lab		Outpatient Medical		CCRC		Other		Total
Equity income (loss) from unconsolidated joint ventures	$	237	$	617	$	539	$	748	$	2,141
Depreciation and amortization	5,245		672		—		13,132		19,049
General and administrative	123		30		—		126		279
Loss (gain) on sales of real estate, net	—		(2)		181		—		179
Other expense (income), net	(1,712)		—		(386)		(1,628)		(3,726)
Income tax expense (benefit)	—		20		—		233		253

Healthpeak's share of unconsolidated joint venture NOI	$	3,893	$	1,337	$	334	$	12,611	$	18,175


			27


Reconciliations


Noncontrolling Interests' Share of Consolidated Joint Venture NOI

In thousands


Total Portfolio	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Income (loss) from continuing operations attributable to noncontrolling interest	$	4,016	$	4,274	$	15,555	$	4,300	$	4,442
Gain on sales of real estate, net	—		—		(11,546)		—		—
Depreciation and amortization	4,696		4,657		4,691		4,593		4,474
Other expense (income), net	82		69		113		40		6
Dividends attributable to noncontrolling interest	(2,350)		(2,379)		(2,342)		(2,561)		(2,540)
Noncontrolling interests' share of consolidated joint venture NOI	$	6,444	$	6,621	$	6,471	$	6,372	$	6,382


Lab	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Income (loss) from continuing operations attributable to noncontrolling interest	$	922	$	1,000	$	1,483	$	1,078	$	1,061
Gain on sales of real estate, net	—		—		(413)		—		—
Depreciation and amortization	13		31		37		52		52
Other expense (income), net	—		(35)		(103)		(84)		(91)
Dividends attributable to noncontrolling interest	(901)		(930)		(901)		(930)		(901)
Noncontrolling interests' share of consolidated joint venture NOI	$	34	$	66	$	103	$	116	$	121


Outpatient Medical	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Income (loss) from continuing operations attributable to noncontrolling interest	$	3,094	$	3,274	$	14,072	$	3,032	$	3,181
Gain on sales of real estate, net	—		—		(11,133)		—		—
Depreciation and amortization	4,683		4,626		4,654		4,541		4,422
Other expense (income), net	82		104		216		124		97
Dividends attributable to noncontrolling interest	(1,449)		(1,449)		(1,441)		(1,441)		(1,439)
Noncontrolling interests' share of consolidated joint venture NOI	$	6,410	$	6,555	$	6,368	$	6,256	$	6,261


Corporate Non-segment	Three Months Ended
	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Income (loss) from continuing operations attributable to noncontrolling interest	$	—	$	—	$	—	$	190	$	200



Dividends attributable to noncontrolling interest	—		—		—		(190)		(200)
Noncontrolling interests' share of consolidated joint venture NOI	$	—	$	—	$	—	$	—	$	—


			28


Reconciliations


Noncontrolling Interests' Share of Consolidated Joint Venture NOI

In thousands

For the nine months ended September 30, 2023


	Lab		Outpatient Medical		Corporate Non-segment		Total
Income (loss) from continuing operations attributable to noncontrolling interest	$	3,622	$	20,285	$	390	$	24,297
Gain on sales of real estate, net	(413)		(11,133)		—		(11,546)
Depreciation and amortization	141		13,617		—		13,758
Other expense (income), net	(277)		438		—		161
Dividends attributable to noncontrolling interest	(2,732)		(4,320)		(390)		(7,442)
Noncontrolling interests' share of consolidated joint venture NOI	$	341	$	18,887	$	—	$	19,228

For the nine months ended September 30, 2022


	Lab		Outpatient Medical		Corporate Non-segment		Total
Income (loss) from continuing operations attributable to noncontrolling interest	$	2,784	$	8,917	$	—	$	11,701
Gain on sales of real estate, net	—		(12)		—		(12)
Depreciation and amortization	59		14,041		—		14,100
Other expense (income), net	5		247		—		252
Dividends attributable to noncontrolling interest	(2,733)		(4,347)		—		(7,080)
Noncontrolling interests' share of consolidated joint venture NOI	$	115	$	18,846	$	—	$	18,961


			29


Reconciliations


REVPOR CCRC(1)

In thousands, except per month data



	Three Months Ended
REVPOR CCRC	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Portfolio Cash Real Estate Revenues(2)	$	122,146	$	125,920	$	127,221	$	130,231	$	133,808
Other adjustments to REVPOR CCRC(3)	—		(47)		—		(184)		(206)
REVPOR CCRC revenues	$	122,146	$	125,873	$	127,221	$	130,046	$	133,603

Average occupied units/month	5,894		5,918		5,908		5,925		5,956
REVPOR CCRC per month(4)	$	6,908	$	7,090	$	7,179	$	7,317	$	7,477


	Three Months Ended
REVPOR CCRC excluding NREF Amortization	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
REVPOR CCRC revenues	$	122,146	$	125,873	$	127,221	$	130,046	$	133,603
NREF Amortization(5)	(19,706)		(21,260)		(19,887)		(20,287)		(20,762)

REVPOR CCRC revenues excluding NREF Amortization	$	102,440	$	104,612	$	107,334	$	109,759	$	112,841

Average occupied units/month	5,894		5,918		5,908		5,925		5,956
REVPOR CCRC excluding NREF Amortization per month(4)	$	5,794	$	5,892	$	6,056	$	6,175	$	6,315


	Three Months Ended
SS REVPOR CCRC	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
SS REVPOR CCRC revenues(6)	$	122,143	$	125,873	$	127,084	$	129,999	$	133,603

SS average occupied units/month	5,894		5,918		5,908		5,925		5,956
SS REVPOR CCRC per month(4)	$	6,908	$	7,090	$	7,171	$	7,314	$	7,477


	Three Months Ended
SS REVPOR CCRC excluding NREF Amortization	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
SS REVPOR CCRC revenues(6)	$	122,143	$	125,873	$	127,084	$	129,999	$	133,603
NREF Amortization(5)	(19,706)		(21,260)		(19,887)		(20,287)		(20,762)

SS REVPOR CCRC revenues excluding NREF Amortization	$	102,436	$	104,612	$	107,197	$	109,712	$	112,841

SS Average occupied units/month	5,894		5,918		5,908		5,925		5,956
SS REVPOR CCRC excluding NREF Amortization per month(4)	$	5,794	$	5,892	$	6,049	$	6,173	$	6,315

_____________________________________

(1)May not foot due to rounding.

(2)See pages 12 and 13 of this document for a reconciliation of Portfolio Cash Real Estate Revenues.

(3)Includes revenue from facilities that are held for sale or sold, facilities in redevelopment or recently completed redevelopments that are not yet stabilized.

(4)Represents the quarter REVPOR CCRC divided by a factor of three.

(5)NREF amortization excludes a recently completed redevelopment that is not yet stabilized as it is already excluded from REVPOR CCRC revenues.

(6)See pages 12 and 13 of this document for a reconciliation of Portfolio Cash Real Estate Revenues - SS.


			30


Reconciliations


REVPOR(1)

In thousands, except per month data


	Three Months Ended
REVPOR	September 30, 2022		December 31, 2022		March 31, 2023		June 30, 2023		September 30, 2023
Portfolio Cash Real Estate Revenues(2)	$	18,905	$	19,024	$	20,566	$	20,278	$	20,567
Other adjustments to REVPOR(3)	(2,371)		(2,423)		(2,532)		(2,365)		(2,456)
REVPOR revenues	$	16,534	$	16,601	$	18,034	$	17,914	$	18,111

Average occupied units/month	1,289		1,302		1,297		1,303		1,320
REVPOR per month(4)	$	4,276	$	4,250	$	4,633	$	4,584	$	4,573

______________________________________

(1)May not foot due to rounding.

(2)See pages 12 and 13 of this document for a reconciliation of Portfolio Cash Real Estate Revenues.

(3)Includes revenue for assets in redevelopment or recently completed redevelopments that are not yet stabilized.

(4)Represents the quarter REVPOR divided by a factor of three.


			31


Reconciliations


Discontinued Operations Reconciliation

The results of discontinued operations during the three and nine months ended September 30, 2023 and 2022 are presented below and are included within the Income (loss) from discontinued operations line of the Consolidated Statements of Operations in the accompanying Earnings Release and Supplemental Report. In order to facilitate reconciliation of amounts through this Discussion and Reconciliation of Non-GAAP Financial Measures and the accompanying Earnings Release and Supplemental Report, detailed financial information for discontinued operations for the three and nine months ended September 30, 2023 and 2022 is presented below (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Revenues:

Resident fees and services	$	—	$	1,284	$	—	$	6,765

Total revenues	—		1,284		—		6,765
Costs and expenses:


Operating	—		1,334		—		6,451


Total costs and expenses	—		1,334		—		6,451
Other income (expense):
Gain (loss) on sales of real estate, net	—		(1,131)		—		1,361
Other income (expense), net	—		(7)		—		12
Total other income (expense), net	—		(1,138)		—		1,373
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	—		(1,188)		—		1,687
Income tax benefit (expense)	—		(110)		—		260
Equity income (loss) from unconsolidated joint ventures	—		—		—		64

Income (loss) from discontinued operations	$	—	$	(1,298)	$	—	$	2,011


			32


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $1.00 par value	PEAK	New York Stock Exchange


No.						Description

99.1						Press Release dated October 30, 2023.

99.2						September 30, 2023, Supplemental Report.

99.3						September 30, 2023, Discussion and Reconciliation of Non-GAAP Financial Measures.

104						Cover Page Interactive Data File (embedded within the inline XBRL document and contained in Exhibit 101).


Date: October 30, 2023
	Healthpeak Properties, Inc.



	By:	/s/ Peter A. Scott
		Peter A. Scott
		Chief Financial Officer